BioStock: Xintela advances to clinical phase in OA and difficult-to-heal wounds in 2022
There has been no shortage of news in 2021 for Xintela. With positive study results in several indications, as well as a newly recruited CEO to lead the subsidiary Targinta, Xintela is looking ahead to 2022 as they are expected enter clinical phase with two of their development projects. BioStock contacted Xintela’s CEO Evy Lundgren-Åkerlund to find out more about the progress in 2021 and the plans for 2022.
Read the full article at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se